USPatentGranted
B1

Preparation of amides and quinazoline derivatives

Granted 6 Nov 2001 · no office action yet

Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Law firm: Law firm · Log in to unlock

Attorney: Attorney · Log in to unlock

Inventors: Wen-Chih Chou, Shyh-Fong Chen, Yann-Yu Lu, Ming-Chen Chou · Examiner: Mukund J. Shah · AU 1611 · TC 1600

Application
516960
filed 1 Mar 2000
Publication
Not published
not published
Patent· this page
US 6,313,293
granted 6 Nov 2001

Life of the patent

4 dated events
⤢ drag to zoom20002002200420062008201020122014201620182020ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

The present invention relates to a process for the preparation of amides, comprising reacting amines with carboxylic acids in the presence of silicon amines. The present invention further relates to a process for the preparation of quinazoline derivatives, comprising reacting amines with carboxylic acids in the presence of silicon amines to obtain amides and contacting the resultant amides with quinazoline.

Description

15 parts
›FIELD OF THE INVENTION

The invention relates to a process for the preparation of amides, comprising reacting amines with carboxylic acids in the presence of silicon amines. The resulting amides are useful as the precursors of anti-hypertension medicines.

›BACKGROUND OF THE INVENTION

An amide unit is a very common functional group and exhibits major features in several important natural products or artificial compounds. A number of compounds with the structure of an amide display a very important character in the synthesis of medicines. For example, these compounds are useful as intermediates or precursors in the synthesis of final medicines. For example, the N-acylalkylenediamines of formula (I′) or (II′) are amides and can be respectively used as the intermediates for the synthesis of the anti-hypertension medicines of formula (I) or (II).

Generally speaking, the synthesis of such type of anti-hypertension medicines is conducted by reacting the quinazolinyl chloride intermediate of formula (III)

with the N-acylalkylenediarnine intermediate of formula (I′) or (II′), to obtain a compound of formula (I) or (II).

As to the synthesis of the intermediate of formula (III), i.e. 4-amino-2-chloro-6,7-dimethoxyquinazoline, DE 2 847 623 and J. Med. Chem . 1987, 30, 49 have fully disclosed the synthesis procedures.

There are a number of known methods for the synthesis of amides. For example, they can be produced by the reaction of amines with esters, which involves known, basic organic chemical reactions. Under heating conditions, the reaction of a primary amine and an ester can directly produce an amide bond. However, such a reaction mostly needs to be conducted in the presence of solvents. As to the amidation reaction of a secondary amine and an ester, it needs to be conducted under the catalysis of Lewis acids, strong bases or enzymes, in addition to the presence of solvents.

The conventional methods for direct conversion of carboxylic acids to amides require either a very high reaction temperature (over 190° C.) or special coupling agents, such as carbodumides, phosphorus agents and uronium salts. These coupling agents require preparation and cause problems in isolation of the desired amidation products.

In recent years, several researchers have dedicated to use a variety of processes to synthesize new N-acylalkylenediarnine intermediates, in order to synthesize new anti-hypertension medicines. For example, DE 2 847 623 and J. Med. Chem . 1987, 30, 49 disclose:

Arch. Pharm . 1994, 327, 661 discloses:

Farmaco . 1996, 51, 551 , J. Med. Chem . 1977, 20, 146 and U.S. Pat. No. 4,026,894 disclose:

Org. Prep. Proced. Int . 1976, 8, 85 discloses:

J. Med. Chem . 1986, 29, 19 discloses:

U.S. Pat. No. 4,093,726 discloses:

In view of the above, conventional processes for the preparation of N-acylalkylenediamine intermediates have the following characteristics:

(1) The processes use the corresponding organic acids as starting materials, activate the starting materials to form acyl chlorides or higher active intermediates such as anhydrides, then react the acyl chlorides or anhydrides with diamines to obtain the desired N-acylalkylenediamines. The reaction procedures of these processes are too complicated and the Yield: is low (about 40%-70%). Also, these processes may produce waste chemicals causing environmental problems.

(2) Since the reactivity of acyl chlorides or anhydrides is very high, one of the amino groups in the diamines used needs to be protected by hydrogen chloride, hydrogen brormide, acetic acid or a tertiary butyloxycarbonyl compound to prevent diamides formation. Subsequently, the deprotection step is required to obtain the desired N-acylalkylenediamines.

Therefore, the object of the present invention is to provide a process for the preparation of amides with simple steps and high Yield:, which simply reacts amines and carboxylic acids in the presence of silicon amines to form amides in situ. The process of the invention does not require the conversion of acids to alkyl esters, neither does it require high reaction temperatures or additional agents.

›SUMMARY OF THE INVENTION

The present invention relates to a process for the preparation of amides, which comprises reacting amines with carboxylic acids in the presence of silicon amines.

This invention further relates to a process for the preparation of quinazoline derivatives, which comprises reacting amines with carboxylic acids in the presence of silicon amines to obtain amides, and contacting the resulting amides with a quinazoline.

›DETAILED DESCRIPTION OF THE INVENTION

The present invention first relates to a process for the preparation of amides, which comprises reacting amines with carboxylic acids in the presence of silicon amines.

The amines suitable for the process for the preparation of amides of the present invention comprise the amines of the following formulae:

wherein R is the same or different and selected from hydrogen, C 1-6 alkyl, and C 2-6 alkenyl; preferably selected from hydrogen and C 1-6 alkyl; most preferably selected from hydrogen and methyl; X is CR or NR, R is as defined above; m is 2 or 3, preferably 2; n is 2 or 3, preferably 2; k is 1 to 8; preferably 3.

The carboxylic acids suitable for the process for the preparation of amides of the present invention comprise the carboxylic acids of the following formula:

wherein R 1 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl, aryl, heterocyclyl, and

wherein Y is selected from hydrogen, C 1-6 alkyl, and C 2-6 alkenyl; R 1 is preferably selected from C 1-6 alkyl, phenyl, 4 to 7 membered heterocyclyl which contains 1 to 3 the same or different hetero atoms selected from nitrogen, oxygen and sulfur, and optionally fused with phenyl or heterocyclyl, and

wherein Y is straight or branch C 1-6 alkyl; Alk is unsubstituted or substituted alkylene, preferably unsubstituted, hydroxyl-substituted or methyl-substituted alkylene; h is 0 to 4, preferably 0 to 2.

The silicon amines suitable for the process for the preparation of amides of the present invention comprise the silicon amines of the following formula:

wherein R 2 is the same or different and selected from hydrogen, C 1-6 alkyl, and C 2-6 alkenyl, preferably unsubstituted C 1-6 alkyl; Z is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, and silyl, preferably C 1-6 alkyl-substituted silyl. Most preferably, the silicon amine is 1,1,1,3,3,3-hexamethyldisilazane, abbreviated as HMDS.

The present invention further relates to a process for the preparation of quinazoline derivatives, comprising reacting amines with carboxylic acids in the presence of silicon amines to obtain amides, and contacting the resulting amides with a quinazoline of the following formula:

wherein R 7 , R 8 , R 9 and R 10 are independently selected from halogen, hydrogen, amino, C 1-8 alkyl, C 2-8 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 6-12 aryl, C 1-8 alkoxy, C 1-8 alkylthio and C 3-8 heterocyclyl.

The amines suitable for the process for the preparation of quinazoline derivatives of the present invention comprise the amines of the following formulae:

wherein R is the same or different and selected from hydrogen, C 1-6 alkyl, and C 2-6 alkenyl; preferably selected from hydrogen and C 1-6 alkyl; most preferably selected from hydrogen and methyl; X is CR or NR, R is as defined above; m is 2 or 3, preferably 2; n is 2 or 3, preferably 2; k is 1 to 8; preferably 3.

The carboxylic acids suitable for the process for the preparation of quinazoline derivatives of the present invention comprise the carboxylic acids of the following formula:

wherein R 1 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl, aryl, heterocyclyl, and

wherein Y is selected from hydrogen, C 1-6 alkyl and C 2-6 alkenyl; R 1 is preferably selected from C 1-6 alkyl, phenyl, 4 to 7 membered heterocyclyl which contains 1 to 3 the same or different hetero atoms selected from nitrogen, oxygen and sulfur, and optionally fused with phenyl or heterocyclyl, and

wherein Y is straight or branch C 1-6 alkyl; Alk is unsubstituted or substituted alkylene, preferably unsubstituted, hydroxyl-substituted or methyl-substituted alkylene; h is 0 to 4, preferably 0 to 2.

The silicon amines suitable for the process for the preparation of quinazoline derivatives of the present invention comprise the silicon amines of the following formula:

wherein R 2 is the same or different and selected from hydrogen, C 1-6 alkyl, and C 2-6 alkenyl, preferably unsubstituted C 1-6 alkyl; Z is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, and silyl, preferably C 1-6 alkyl-substituted silyl. Most preferably, the silicon amine is 1,1,1,3,3,3-hexamethyldisilazane, abbreviated as HMDS.

The term “C 1-6 alkyl” represents straight or branch alkyl having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, tert-pentyl, and hexyl. The term “C 2-6 alkenyl” represents straight or branch alkenyl having 2 to 6 carbon atoms and having at least one double bond in any position, for example, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, and 5-hexenyl. The term “aryl” represents aromatic mono- or poly-cyclohydrocarbyl, for example, phenyl and naphthyl. The term “heterocyclyl” represents saturated, partially saturated, or unsaturated heterocyclyl, in which, in addition to carbon atoms, the ring additionally contains hetero atoms selected from oxygen, sulfur and nitrogen. The term “alkylene” represents substituent —CH 2 —. The term “silyl” represents substituent —SiH 3 . C 1-6 alkyl, C 2-6 alkenyl, aryl, heterocyclyl, alkylene, and silyl can be substituted with one or more substitutents such as C 1-6 alkyl and hydroxyl.

The amidation reactions of the present invention comprise adding silicon amines into the mixtures of amines and carboxylic acids in the present of nitrogen air under moderate temperatures (between 70-200° C., preferably 75-150° C.); stirring the mixtures for several hours till the amidation reactions complete; after cooling, distributing the mixtures in a proper solvent, such as the aqueous solution of chloroform and sodium hydrogen carbonate; washing the organic layer, for example, with water; drying, for example, with anhydrous sodium sulfate; and carrying to chromatography, to obtain the desired amide products. The Yield: is between 72-93%.

The feasibility of the present invention is illustrated by the following examples which are provided for illustration but not for limitation of the scope of the invention.

WORKING EXAMPLES
›Examples10
›Example 1

The preparation of N-(tetrahydrofuran-2-carbonyl) piperazine (Compound 3)

In a 100 ml round-bottom flask, tetrahydrofuran-2-carboxylic acid (3.48 grams, 30 mmole), piperazine (5.16 grams, 60 mmole) and 1,1,1,3,3,3-hexamethyldisilazane (4.83 grams, 30 mmole) were added, stirred under a nitrogen atmosphere and heated to 110° C. After 5 hours, the completion of the reaction was detected by thin-layer chromatography (TLC). After cooling to room temperature, the product was dissolved in chloroform, washed with a sodium hydrogen carbonate solution once and with water once. The organic layer was dried with anhydrous sodium sulfate, filtered, and applied suction to obtain 5.13 grams of Compound 3.

Yield:: 93%.

Compound 3: 1 H NMR (CDCl 3 ) δ 1.87-1.91 (m, 1 H), 1.93-2.07 (m, 2 H), 2.22-2.27 (m, 1 H), 2.45 (s, 1 H, NH), 2.85-2.91 (m4 H), 3.48-3.57 (m, 2 H), 3.60-3.69 (m, 2 H), 3.86-3.90 (m, 1 H), 3.93-3.99 (m, 1 H), 4.61 (dd, J=7.3, 5.4 Hz, 1 H); 13 C NMR (CDCl 3 ) δ 25.6 (t), 28.4 (t), 43.0 (t), 45.8 (t), 46.2 (t), 46.6 (t), 68.9 (t), 75.6 (d), 169.8 (s)

›Example 2

The preparation of N-(1,4-benzodioxane-2-carbonyl) pierazine (Compound 4)

The procedures of Example 1 were followed except that 1,4-benzodioxane-2-carboxylic acid (3.6 grams, 20 mmole), piperazine (3.44 grams, 40 mmole) and 1,1,1,3,3,3-hexamethyldisilazane (6.44 grams, 40 mmole) were reacted for 5 hours under 110° C. After extraction purification, 4.51 grams of Compound 4 was obtained. Yield: 91%.

Compound 4: 1 H NMR (CDCl 3 ) δ 2.20 (s, 1 H, NH), 2.90-2.95 (m,.2 H), 2.95-3.00 (m, 2 H), 3.56-3.61 (m, 2 H), 3.75-3.82 (m, 2 H), 4.37 (dd, J=11.9, 8.2 Hz, 1 H), 4.53 (dd, J=11.9, 2.5 Hz, 1 H), 4.87 (dd, J=8.2, 2.5 Hz, 1 H), 6.88-6.96 (m, 4 H); 13 C NMR (CDCl 3 ) δ 43.2 (t), 45.8 (t), 46.4 (t), 47.0 (t), 65.2 (t), 70.5 (d), 117.3 (d), 117.4 (d), 121.5 (d), 122.2 (d), 142.6 (s), 143.3 (s), 164.8 (s)

›Example 3

The preparation of N-(furan-2-carbonyl) piperazine (Compound 5)

In a 100 ml round-bottom flask, furan-2-carboxylic acid (3.9 grams, 35 mmole), piperazine (6.02 grams, 70 mmole) and 1,1,1,3,3,3-hexamethyldisilazane (11.27 grams, 70 mmole) were added, stirred under a nitrogen atmosphere and heated to 110° C. After 3 hours, the completion of the reaction was detected by thin-layer chromatography (TLC). After cooling to room temperature, the product was dissolved in dichloromethane, extracted with a 0.5 N hydrochloric acid solution to form an organic layer and an aqueous layer. The organic layer was washed with a sodium hydrogen carbonate solution once and with water once, dried with anhydrous sodium sulfate, filtered, and applied suction to obtain 0.48 grams of diamide (Compound 5′). The aqueous layer was alkalified with a potassium carbonate solution to pH 10 and extracted with chloroform. The extract was dried with anhydrous sodium sulfate, filtered and applied suction to obtain 5.3 grams of Compound 5. Yield: 83%.

Compound 5: 1 H NMR (CDCl 3 ) δ 2.27 (br s, 1 H, NH), 2.92-2.96 (m, 4 H), 3.79 (br s, 4 H), 6.49 (dd, J=3.5, 1.8 Hz, 1 H), 7.00 (dd, J=3.5, 0.8 Hz, 1 H), 7.50 (dd, J=1.8, 0.8 Hz, 1 H); 13 C NMR (CDCl 3 , −50° C.) δ 43.3 (t), 45.7 (t), 46.3 (t), 47.7 (t), 111.4 (d), 116.4 (d), 144.2 (d), 146.8 (s), 159.2 (s)

›Example 4

The preparation of N-(3-trimethylsiloxybutylcarbonyl) piperazine (Compound 6)

The procedures of Example 1 were followed except that 3-hydroxylbutric acid (3.4 grain s, 33 mmole), piperazine (5.7 grams, 66 mmole) and 1,1, 1,3,3,3-hexamethyldisilazane (10.6 grams, 66 mmole) were reacted for 5 hours under 110° C. After extraction purification, 6.7 grams of Compound 6 was obtained. Yield: 83%.

Compound 6: 1 H NMR (CDCl 3 ) δ 0.11 (s, 9 H), 1.24 (d, J=6.1 Hz, 3 H), 2.33 (dd, J=14.2, 5.2 Hz, 1 H), 2.64 (dd, J=14.2, 7.3 Hz, 1 H), 2.66 (br s, 1 H, NH), 2.86-2.91 (m, 4 H), 3.48-3.66 (m, 4 H), 4.33 (ddt, J=7.3, 6.1, 5.2 Hz, 1 H); 13 C NMR (CDCl 3 ) 1.38, 24.26, 42.44, 42.67, 45.73, 46.05, 47.15, 66.61, 169.85

›Example 5

The preparation of N-methyl-N-tetrahydrofuran-2-carbonyl trimethylene diamine (Compound 7)

The procedures of Example 1 were followed except that tetrahydrofuran-2-carboxylic acid (3.7 grains, 30 mmole), N-methyl triethylene diamine (5.3 grams, 60 mmole) and 1,1,1,3,3,3-hexamethyldisilazane (9.7 grams, 60 mmole) were reacted for 5 hours under 110° C. After extraction purification, 4.7 grams of Compound 7 was obtained. Yield: 85%.

Compound 7: 1 H NMR (CDCl 3 ) δ 1.63-1.68 (mn, 2 H), 1.73 (br s, 1 H, NH), 1.81-1.89 (mn, 2 H), 1.98-2.05 (mn, 1 H), 2.17-2.26 (m, 1 H), 2.39 (s, 3 H), 2.57-2.64 (m, 2 H), 3.26-3.34 (m;,2 H), 3.80-3.85 (m, 1 H), 3.86-3.91 (m, 1 H), 4.30 (dd, J=8.4, 5.7 Hz, 1 H), 7.22 (br s, 1 H, NH); 13 C NMR (CDCl 3 ) δ 25.4 (t), 28.9 (t), 30.2 (t), 36.1 (q), 37.3 (t), 49.6 (t), 69.2 (t), 78.4 (d), 173.2 (s)

›Example 6

The preparation of N-(thiophene-2-carbonyl)piperazine (Compound 8)

The procedures of Example 3 were followed except that thiophene-2-carboxylic acid (4.5 grams, 35 mmole), piperazine (6.0 grams, 70 mmole) and 1,1,1,3,3,3-hexamethyldisilazane (11.3 grams, 70 mmole) were reacted under 110° C. After extraction purification, 5.7 grams of Compound 8 (Yield: 72%) and 0.97 grams of diamide (Compound 8′) were obtained.

Compound 8: 1 H NMR (CDCl 3 ) δ 2.08 (s, 1 H, NH), 2.89-2.93 (m, 4 H), 3.70-3.74 (m, 4 H), 7.04 (dd, J=5.1, 3.7 Hz, 1 H), 7.28 (dd, J=3.7, 1.1 Hz, 1 H), 7.44 (dd, J=5.1, 1.1 Hz, 1 H); 13 C NMR (CDCl 3 −50° C.) δ 43.5 (t), 45.6 (t), 46.3 (t), 48.9 (t), 126.9 (d), 128.9 (d), 129.1 (d), 136.6 (s), 163.7 (s)

›Example 7

The preparation of N-(2-tert-butoxycarbonyl-aminopropyl-carbonyl) piperazine (Compound 9)

The procedures of Example 1 were followed except that Compound if (5.6 grams, 30 mmole), piperazine (5.2 grams, 60 mmole) and 1,1,1,3,3,3-hexamethyldisilazane (9.7 grams, 60 mmole) were reacted for 5 hours under 110° C. After extraction purification, 6.7 grams of Compound 9 was obtained. Yield: 87%.

Compound 9: a colorless solid, melting point 142.0-142.5° C., 1 H NMR (CDCl 3 ) δ 1.27 (d, J=6.9 Hz, 3 H), 1.41 (s, 9 H), 2.10 (brs, 1 H, NH) 2.81-2.88 (m, 4 H) 3.40-3.43 (m, 1 H) 3.47-3.54 (m, 2 H), 3.58-3.61 (m, 1 H), 4.58 (dq, J=7.5, 6.9 Hz, 1 H), 5.59 (d, J=7.5 Hz, 1 H, amide NH); 13 C NMR (CDCl 3 ) δ 19.36, 28.35, 42.84, 45.61, 45.99, 46.05, 46.33, 79.05, 155.07, 171.15

When the reaction conditions were changed to the temperature of 75° C. and the reaction time of 12 hours, after extraction purification, 3.9 grams of Compound 9 was obtained. Yield: 40%. After determination, the optical rotation was [α] D 23 −18.5°(c 0.2, MeOH). 91% of enantiomeric was retained.

›Example 8

The preparation of N-(benzylcarbonyl)piperazine (Compound 10)

The procedures of Example 1 were followed except that phenyl acetic acid (3.4 grams, 25 mmole), piperazine (4.3 grams, 50 mmole) and 1,1,1,3,3,3-hexamethyldisilazane (4.0 grams, 25 mmole) were reacted for 5 hours under 110° C. After extraction purification, 4.2 grams of Compound 10 was obtained. Yield: 82%.

Compound 10 was transparent liquid: 1 H NMR (CDCl 3 ) δ 1.33-1.37 (m, 2 H), 1.51-1.54 (m, 2 H) , 1.56-1.59 (m, 2 H) , 3.37 (t, J=5.5 Hz, 2 H), 3.58 (t, J=5.5 Hz, 2 H) , 3.73 (s, 2 H), 7.21-7.28 (m, 3 H), 7.29-7.33 (m, 2 H)

›Example 9

The preparation of anti-hypertension medicines, Doxazosin

4-Amino-2-chloro-6,7-bismethoxyquinazoline (III) (3.2 grams, 13.35 mmole), Compound 4 from Example 2 (3.4 grains, 13.75 mmole) and n-butanol (72 ml) were subjected to a 50 ml round-bottom flask and heated under refluxing for 3.5 hours under a nitrogen atmosphere. Cooling to 75° C., the solid products were filtered and collected, dried in an oven to obtain 5.25 grams of Doxazosin hydrochloride (10.76 mmole, Yield: 81%). The Doxazosin hydrochloride was added to a 1N NaOH solution and heated for dissolution. After cooling, the solution was extracted with 150 ml of dichloromethane twice. The organic layer was filtered and dried with anhydrous sulfate, and concentrated to obtain 4.61 grams of white Doxazosin solid: 1 H NMR (CDCl 3 ) δ 3.63-4.09 (m, 8 H), 3.91 (s, 3H), 3.96 (s, 3H), 4.35 (dd, J=11.9, 7.9 Hz, 1H), 4.52 (dd, J=11.9, 2.4 Hz, 1H), 4.88 (dd, J=7.9, 2.4 Hz, 1H), 6.85-6.95 (m, 5H)

›Example 10

The preparation of anti-hypertension medicines, Terazosin

The procedures of Example 9 were followed except that Compound 3 from Example 1 (3.0 grams, 16.3 mmole) and 4-amino-2-chloro-6,7-bismethoxy quinazoline III (3.8 grams, 16.1 mmole) were reacted to obtain 5.0 grams of Terazosin hydrochloride (Yield: 73%). After alkalification, 4.7 grams of white Terazosin solid was obtained.

Comparative Example 1

The procedures of Example 1 were followed except that tetrahydrofuran-2-carboxylic acid (0.9 grams, 5 mmole), piperazine (0.86 grams, 10 mmole) and chlorotrimethylsilane (0.54 grams, 5 mmole) were reacted for 5 hours under 110° C. The reaction product was solid. No desired amide products were obtained after analysis.

As various changes could be made in the above processes without departing from the scope of the present invention, it is intended that the above-described specific working examples be interpreted as illustrative and not in a limiting sense.

Claims

20 · 2 independent · depth 3
1234567891011121314151617181920
20 granted claims

Classifications

14 codes
IPC · International Patent Classification
Section C — Chemistry; metallurgy
  • C07D319/16
  • C07C231/02
  • C07D405/12
  • C07D307/24
  • C07D295/182
  • C07D333/38
  • C07F7/18
USPC · US Patent Classification
544/283556/410544/377544/374549/487556/412544/386

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency
1.7 y
615 days filing → grant
Office actions
0
on the grant's record
Examiner
Mukund J. Shah
art unit 1611 · TC 1600
Citations: 9 back · 1 forward

Chain of title

⤢ drag to zoom20002002200420062008201020122014201620182020Owner 1
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Log in to unlock

Worldwide family

2 members · 2 offices
US1TW1
this patentIP5 & PCTother officessolid = grantedhover for detail · click to open
Members
2
DOCDB simple family 21640123
Offices
2
US
Granted
2 of 2
grant date present
›IP5 & PCT — 1 members
OfficePublicationKindPublishedFiledStatusTitle
USthis patentUS-6313293-B1B16 Nov 20011 Mar 2000grantedPreparation of amides and quinazoline derivatives
›Other offices — 1 members
OfficePublicationKindPublishedFiledStatusTitle
TWTW-448155-BB1 Aug 200129 Mar 1999grantedMethod for producing amide compounds and quinazolin derivatives

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Log in to unlock

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.

Log in to unlock